A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Clinical trial NCT03940703 · COMPLETED

Trial details

NCT number: NCT03940703
Sponsor: EMD Serono Research & Development Institute, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2019-09-19
Primary completion: 2023-05-11
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.